Detail akcie VolitionRX online

Business Summary: VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, VolitionRX Ltd revenues increased 23% to $1.3M. Net loss decreased 19% to $17.1M. Revenues reflect Services increase of 63% to $366K, Product increase of 12% to $914K. Lower net loss reflects Direct research and development expenses decrease of 60% to $1.5M (expense), Personnel expenses - R&D decrease of 25% to $4.5M (expense), Personnel expenses-S&A decrease of 34% to $2.1M (expense).